The microRNAs within the DLK1-DIO3 genomic region: involvement in disease pathogenesisLeonidas Benetatos
Transfusion Unit, General Hospital of Preveza, Selefkias 2, 48100, Preveza, Greece
Cell Mol Life Sci 70:795-814. 2013
..The potential clinical implications of this data are also discussed...
- Deregulated microRNAs in multiple myeloma
Leonidas Benetatos
Department of Hematology, University Hospital of Ioannina, Ioannina, Greece
Cancer 118:878-87. 2012
..Further studies are needed to better understand their role in myelomagenesis and their therapeutic potential...
DLK1-MEG3 imprinted domain microRNAs in cancer biologyLeonidas Benetatos
Transfusion Unit, General Hospital of Preveza, Preveza, Greece
Crit Rev Eukaryot Gene Expr 22:1-15. 2012
..Moreover, as they can be detected in patients' serum, are easy to obtain, and can be used as adjuvant diagnostic biomarkers with the potential of monitoring disease progression and response to treatment...
- Promoter hypermethylation of the MEG3 (DLK1/MEG3) imprinted gene in multiple myeloma
Leonidas Benetatos
Department of Hematology, University Hospital of Ioannina, Greece
Clin Lymphoma Myeloma 8:171-5. 2008
..MEG3 represents an imprinted gene maternally expressed in humans that encodes a nontranslated product. In this survey, we studied the methylation status of the specific gene in multiple myeloma (MM)...
- MEG3 imprinted gene contribution in tumorigenesis
Leonidas Benetatos
Department of Hematology, University Hospital of Ioannina, Ioannina, Greece
Int J Cancer 129:773-9. 2011
..MEG3 could represent a tumor suppressor gene located in chromosome 14q32 and its association with tumorigenesis is growing every day...
- Polo-like kinase 2 (SNK/PLK2) is a novel epigenetically regulated gene in acute myeloid leukemia and myelodysplastic syndromes: genetic and epigenetic interactions
Leonidas Benetatos
Department of Hematology, University Hospital of Ioannina, Niarchos Avenue, 45500 Ioannina, Greece
Ann Hematol 90:1037-45. 2011
..As such, SNK/PLK2 could represent a potential pathogenetic factor, although additional studies are necessary to verify its exact role in disease pathogenesis...
- CpG methylation analysis of the MEG3 and SNRPN imprinted genes in acute myeloid leukemia and myelodysplastic syndromes
Leonidas Benetatos
Department of Hematology, University Hospital of Ioannina, Niarchos Avenue, 45500 Ioannina, Greece
Leuk Res 34:148-53. 2010
..Our findings suggest that these genes are abnormally methylated in AML and MDS patients, and methylation of MEG3 confers worse overall prognosis. The MEG3 methylation status may serve as a useful biomarker in leukemia...
- Absence of methylation-dependent transcriptional silencing in TP73 irrespective of the methylation status of the CDKN2A CpG island in plasma cell neoplasia
Eleftheria Hatzimichael
Department of Haematology, University Hospital of Ioannina, St Niarchou Av, 45 500 Ioannina, Greece
Leuk Res 33:1272-5. 2009
..Further evaluation in a larger sample of patients is needed in order to enhance our statistical power and to test our hypothesis that CDKN2A methylation status can become a useful prognostic biomarker...
- Bcl2-interacting killer CpG methylation in multiple myeloma: a potential predictor of relapsed/refractory disease with therapeutic implications
Eleftheria Hatzimichael
Department of Hematology, University Hospital of Ioannina, Ioannina, Greece
Leuk Lymphoma 53:1709-13. 2012
..These findings warrant validation in larger cohorts of patients and suggest therapeutic utility for agents that enhance BIK expression...
- Study of specific genetic and epigenetic variables in multiple myeloma
Eleftheria Hatzimichael
Department of Hematology, University Hospital of Ioannina, Ioannina, Greece
Leuk Lymphoma 51:2270-4. 2010
..Further evaluation in a larger sample of patients is needed in order to better define the prognostic and clinical value, if any, of MTHFR 1298 polymorphisms and CDKN2A and Snk/Plk2 methylation in the pathogenesis of MM...
- Von Hippel-Lindau methylation status in patients with multiple myeloma: a potential predictive factor for the development of bone disease
Eleftheria Hatzimichael
Department of Haematology, Haematology Research Laboratory, University Hospital of Ioannina, Ioannina, Greece
Clin Lymphoma Myeloma 9:239-42. 2009
..Whether it represents an early or late event of the disease merits additional study. Additional studies regarding the serum levels of HIF-1alpha and vascular endothelial growth factor would be mechanistically interesting...
Gene mutations and molecularly targeted therapies in acute myeloid leukemiaEleftheria Hatzimichael
Department of Hematology, University of Ioannina Ioannina, Greece
Am J Blood Res 3:29-51. 2013
....
- Peripheral blood flow cytometry based diagnosis in primary cutaneous aggressive epidermotropic CD8+ T-cell lymphoma: implications for more extensive use
Leonidas Benetatos
Department of Haematology, University Hospital of Ioannina, Greece
Cytometry B Clin Cytom 76:102-6. 2009
..Perhaps, more than one antibody should be used in primary cutaneous aggressive epidermotropic CD8-positive T-cell lymphomas, in order to be more accurate in the diagnosis and so in the classification of such diseases...
- The absence of CDKN1C (p57KIP2) promoter methylation in myeloid malignancies also characterizes plasma cell neoplasms
Eleftheria Hatzimichael
Br J Haematol 141:557-8. 2008
- Non-secretory multiple myeloma with involvement of the hand as initial manifestation
Leonidas Benetatos
Leuk Lymphoma 47:1677-9. 2006
